Table 2 Incidence rates of malignancy in early rheumatoid arthritis patients by sex

All malignancies

725

174.3 (161.6–187.0)

266

280.4 (246.7–314.1)

459

142.9 (129.9–156.0)

 Lip, oral cavity, and pharynx

9

2.2 (0.8–3.6)

5

5.3 (0.7–9.9)

4

1.2 (0.0–2.5)

 Esophagus

3

0.7 (0.1–1.5)

3

3.2 (0.4–6.7)

–

–

 Stomach

61

14.7 (11.0–18.3)

31

32.7 (21.2–44.2)

30

9.3 (6.0–12.7)

 Colon and rectum

84

20.2 (15.9–24.5)

28

29.5 (18.6–40.4)

56

17.4 (12.9–22.0)

 Liver

52

12.5 (9.1–15.9)

22

23.2 (13.5–32.9)

30

9.3 (6.0–12.7)

 Gallbladder

10

2.4 (0.9–3.9)

2

2.1 (0.8–5.0)

8

2.5 (0.8–4.2)

 Pancreas

50

12.0 (8.7–15.4)

13

13.7 (6.3–21.2)

37

11.5(7.8–15.2)

 Larynx

5

1.2 (0.1–2.3)

5

5.3 (0.7–9.9)

–

–

 Lung

60

14.4 (10.8–18.1)

33

34.8 (22.9–46.7)

27

8.4 (5.2–11.6)

 Breast

39

9.4 (6.4–12.3)

1

1.1 (1.0–3.1)

38

11.8 (8.1–15.6)

 Cervix uteri

17

4.1 (2.1–6.0)

0

–

17

5.3 (2.8–7.8)

 Corpus uteri

4

1.0 (0.0–1.9)

0

–

4

1.2 (0.0–2.5)

 Ovary

13

3.1 (1.4–4.8)

0

–

13

4.0 (1.8–6.2)

 Prostate

47

11.3 (8.1–14.5)

47

49.5 (35.4–63.7)

0

–

 Testis

3

0.7 (0.09–1.5)

3

3.2 (0.4–6.7)

0

–

 Kidney

8

1.9 (0.6–3.3)

4

4.2 (0.1–8.3)

4

1.2 (0.0–2.5)

 Bladder

14

3.4 (1.6–5.1)

8

8.4 (2.6–14.3)

6

1.9 (0.4–3.4)

 Brain and CNS

5

1.2 (0.1–2.3)

1

1.1 (1.0–3.1)

4

1.2 (0.0–2.5)

 Thyroid

87

20.9 (16.5–25.3)

5

5.3 (0.7–9.9)

82

25.5 (20.0–31.1)

Hematologic malignancy

21

5 (2.9–7.2)

6

6.3 (1.3–11.4)

15

4.7 (2.3–7.0)

 Hodgkin lymphoma

1

0.2 (0.2–0.7)

0

–

1

0.3 (0.3–0.9)

 Non-Hodgkin lymphoma

13

3.1 (1.4–4.8)

4

4.2 (0.1–8.3)

9

2.8 (1.0–4.6)

 Multiple myeloma

1

0.2 (0.2–0.7)

0

–

1

0.3 (0.3–0.9)

 Leukemia

6

1.4 (0.3–2.6)

2

2.1 (0.8–5.03)

4

1.2 (0.0–2.47)

Others

133

32.0 (26.5–37.4)

49

51.7 (37.2–66.1)

84

26.2 (20.6–31.8)